10-K: Hestia Insight Inc. Reports Increased Revenue in Fiscal Year 2024 Amid Going Concern Uncertainty

Hestia Insight Inc. reports a significant increase in revenue for the fiscal year ended November 30, 2024, but acknowledges substantial doubt about its ability to continue as a going concern.

Summary

• Hestia Insight Inc. filed its annual report on Form 10-K for the fiscal year ended November 30, 2024.
• The company's revenue increased significantly from $113,413 in 2023 to $1,249,884 in 2024, primarily due to an increase in consulting revenue.
• Despite the revenue increase, the company reported an accumulated deficit of $(114,323) as of November 30, 2024.
• The company's independent auditor has raised substantial doubt about its ability to continue as a going concern, citing insufficient cash to cover operating expenses for the next twelve months.
• Hestia Insight Inc. operates through two subsidiaries: Hestia Investments, providing consulting services, and HSTA HEALTH INC., operating in the healthy vending machine industry.
• The company is pursuing acquisitions and development of healthcare-related technologies.
• The company's common stock is traded on OTC Markets under the symbol HSTA.
• As of March 17, 2025, there were 27,939,260 shares of common stock outstanding.
• The market value of the company's common stock held by non-affiliates as of November 30, 2024, was $4,432,530.
• The company's officers and directors and affiliates own approximately 68.27% of the outstanding common shares.

Sentiment

Score: 4

Explanation: While revenue increased, the going concern warning and ineffective internal controls raise significant concerns, resulting in a negative sentiment.

Positives

• The company experienced a significant increase in revenue during the fiscal year 2024.
• The company is actively pursuing opportunities in the healthcare and biotech sectors.
• The company has established strategic partnerships to expand its business operations.
• The company is exploring emerging healthcare technologies through acquisitions, licensing, or joint ventures.

Negatives

• The company has an accumulated deficit of $(114,323) as of November 30, 2024.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company relies heavily on direct management oversight and outside consultants due to limited resources and employees.
• The company's internal controls over financial reporting were deemed ineffective as of November 30, 2024.

Risks

• The company's limited operating history makes it difficult to evaluate future business prospects.
• The company's business requires substantial capital, and the inability to maintain adequate financing sources could jeopardize its ability to continue operations.
• The company faces intense competition in the healthcare markets.
• The company is dependent on key personnel, and their departure could have a material adverse effect on the business.
• The company's growth depends on external sources of capital, which may not be available on favorable terms or at all.
• The company may be deemed an investment company under the Investment Company Act of 1940, which would restrict its operations.
• The company's strategic consulting and capital market advisory services may be affected by the current COVID-19 pandemic.
• The current political tension between the United States and China can adversely affect the company.

Future Outlook

The company intends to pursue the acquisition and development of healthcare-related technologies in the healthcare and biotech sectors through acquisition, licensing, or joint ventures.

Industry Context

The company operates in the highly regulated and rapidly changing healthcare industry, which is subject to political, legislative, and regulatory influences.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• Without specific financial benchmarks for comparable companies in the healthcare consulting and vending machine industries, a thorough assessment is not possible.
• A comprehensive comparison would require analyzing metrics such as revenue growth, profitability, and market share against industry averages and key competitors like Accenture (in consulting) or Selecta (in vending).

Related Party Transactions

• On January 15, 2024, the Company entered into a $50,000 note payable to ECL Capital Partners Corp, a related party.
• During the nine months ended May 31, 2024 an additional loan of $3,931 from Mr. Edward C. Lee was received as a short-term loan, bearing no interest.
• On August 25, 2024, the Company entered into a $25,000 note payable to ECL Capital Partners Corp, a related party.

Stakeholder Impact

• Shareholders face the risk of losing their entire investment if the company is unable to continue as a going concern.
• Employees' job security is uncertain due to the company's financial challenges.
• Customers may be affected if the company is unable to provide its services.
• Suppliers and creditors face the risk of non-payment if the company's financial situation deteriorates.

Next Steps

• The company needs to secure additional financing to fund its operations and address its working capital requirements.
• The company needs to improve its internal controls over financial reporting.
• The company intends to pursue the acquisition and development of healthcare-related technologies.

Key Dates

Keywords

Hestia Insight, financial results, Form 10-K, healthcare, biotech, consulting, vending machines, going concern, revenue, risk factors, financial statements, capital markets, advisory services